CHAPTER 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

CHAPTER 2 EXECUTIVE SUMMARY

2.1.1. CXO perspective

CHAPTER 3 MARKET OVERVIEW

3.1. REPORT DESCRIPTION
3.2. KEY BENEFITS

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.3. PATENT ANALYSIS

3.3.1. Patent analysis by year
3.3.2. Patent analysis by region

3.4. GOVERNMENT REGULATIONS
3.5. MARKET DYNAMICS

3.5.1. Drivers

3.5.1.1. Increased stringency of regulatory authorities concerning environment welfare
3.5.1.2. Replacement of in vivo models by in vitro model
3.5.1.3. Increased stringency of regulatory authorities concerning public health welfare
3.5.1.4. Adoption of early toxicity in order to reduce drug failure in later stages

3.5.2. Restrains

3.5.2.1. Limited awareness about the benefits of early toxicity testing
3.5.2.2. Limitation of preclinical testing

3.5.3. Opportunities

3.5.3.1. Advancement in in silico platforms
3.5.3.2. Advancement in in vitro models

CHAPTER 4 GLOBAL EARLY TOXICITY TESTING MARKET, BY TECHNIQUE

4.1. OVERVIEW

4.1.1. Market size and forecast

4.2. IN VIVO

4.2.1. Key market trends
4.2.2. Key growth factors and opportunities
4.2.3. Market size and forecast

4.3. IN VITRO

4.3.1. Key market trends
4.3.2. Key growth factors and opportunities
4.3.3. Market size and forecast
4.3.4. In vitro toxicity testing market by assays

4.3.4.1. Enzyme toxicity assays

4.3.4.1.1. Market size and forecast

4.3.4.2. Bacterial toxicity assays

4.3.4.2.1. Market size and forecast

4.3.4.3. Cell-based ELISA and western blots

4.3.4.3.1. Market size and forecast

4.3.4.4. Tissue culture assays

4.3.4.4.1. Market size and forecast

4.3.4.5. Receptor binding assays

4.3.4.5.1. Market size and forecast

4.3.4.6. Other assays

4.3.4.6.1. Market size and forecast

4.3.5. In vitro toxicity testing market by toxicity end-points

4.3.5.1. Dermal toxicity

4.3.5.1.1. Market size and forecast

4.3.5.2. Systemic toxicity

4.3.5.2.1. Market size and forecast

4.3.5.3. Carcinogenicity

4.3.5.3.1. Market size and forecast

4.3.5.4. Ocular toxicity

4.3.5.4.1. Market size and forecast

4.3.5.5. Skin sensitization and irritation

4.3.5.5.1. Market size and forecast

4.3.5.6. Genotoxicity

4.3.5.6.1. Market size and forecast

4.3.5.7. Neurotoxicity

4.3.5.7.1. Market size and forecast

4.3.5.8. Organ toxicity

4.3.5.8.1. Market size and forecast

4.3.5.9. Other toxicity endpoints

4.3.5.9.1. Market size and forecast

4.4. IN SILICO

4.4.1. Key market trends
4.4.2. Key growth factors and opportunities
4.4.3. Market size and forecast

CHAPTER 5 EARLY TOXICITY TESTING MARKET, BY END USERS

5.1. OVERVIEW

5.1.1. Key market trends
5.1.2. Key growth factors and opportunities
5.1.3. Market size and forecast

5.2. PHARMACEUTICAL INDUSTRY

5.2.1. Market size and forecast

5.3. DIAGNOSTICS INDUSTRY

5.3.1. Market size and forecast

5.4. FOOD INDUSTRY

5.4.1. Market size and forecast

5.5. CHEMICALS INDUSTRY

5.5.1. Market size and forecast

5.6. COSMETICS INDUSTRY

5.6.1. Market size and forecast

5.7. OTHER INDUSTRY

5.7.1. Market size and forecast

CHAPTER 6 EARLY TOXICITY TESTING MARKET, BY GEOGRAPHY

6.1. OVERVIEW

6.1.1. Market size and forecast

6.2. NORTH AMERICA

6.2.1. Key market trends
6.2.2. Key growth factors and opportunities
6.2.3. Market size and forecast
6.2.4. U.S. market size & forecast
6.2.5. Canada market size & forecast
6.2.6. Mexico market size & forecast

6.3. EUROPE

6.3.1. Key market trends
6.3.2. Key growth factors and opportunities
6.3.3. Market size and forecast
6.3.4. Germany market size & forecast
6.3.5. France market size & forecast
6.3.6. U.K. market size & forecast
6.3.7. Rest of Europe market size & forecast

6.4. ASIA-PACIFIC

6.4.1. Key market trends
6.4.2. Key growth factors and opportunities
6.4.3. Market size and forecast
6.4.4. Japan market size & forecast
6.4.5. China market size & forecast
6.4.6. Australia market size & forecast
6.4.7. India market size & forecast
6.4.8. Rest of Asia Pacific market size & forecast

6.5. LAMEA

6.5.1. Key market trends
6.5.2. Key growth factors and opportunities
6.5.3. Market size and forecast
6.5.4. Brazil market size & forecast
6.5.5. Republic of South Africa market size & forecast
6.5.6. Rest of LAMEA market size & forecast

CHAPTER 7 COMPANY PROFILES

7.1. THERMO FISHER SCIENTIFIC INC

7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Operating business segments
7.1.4. Product portfolio
7.1.5. Business performance

7.2. BIO-RAD LABORATORIES, INC.

7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Operating business segments
7.2.4. Product portfolio
7.2.5. Business performance

7.3. AGILENT TECHNOLOGIES INC.

7.3.1. Company overview
7.3.2. Operating business segments
7.3.3. Product portfolio
7.3.4. Business performance

7.4. QUEST DIAGNOSTICS INCORPORATION

7.4.1. Company overview
7.4.2. Operating business segments
7.4.3. Product portfolio
7.4.4. Business performance

7.5. MERCK KOMMANDITGESELLSCHAFT AUF AKTIEN

7.5.1. Company overview
7.5.2. Operating business segments
7.5.3. Product portfolio
7.5.4. Business performance
7.5.5. Key strategic moves & developments, 2014-2016

7.6. CHARLES RIVER LABORATORIES INTERNATIONAL INCORPORATION

7.6.1. Company overview
7.6.2. Operating business segments
7.6.3. Product portfolio
7.6.4. Business performance
7.6.5. Key strategic moves & developments, 2014-2016

7.7. BECTON, DICKINSON AND COMPANY

7.7.1. Company overview
7.7.2. Operating business segments
7.7.3. Product portfolio
7.7.4. Business performance

7.8. DANAHER CORPORATION

7.8.1. Company overview
7.8.2. Company snapshot
7.8.3. Operating business segments
7.8.4. Product portfolio
7.8.5. Business performance

7.9. EVOTEC AG

7.9.1. Company overview
7.9.2. Operating business segments
7.9.3. Product portfolio
7.9.4. Business performance
7.9.5. Key strategic moves & developments, 2014-2016

7.10. THE JACKSON LABORATORY

7.10.1. Company overview
7.10.2. Product portfolio
7.10.3. Business performance
7.10.4. Key strategic moves & developments, 2014-2016